All Pharmacy Pearls

Why It Matters

P2Y12 inhibitors reduce ischemic complications in acute coronary syndrome, but the timing of loading in NSTE-ACS is more nuanced than loading every patient immediately. The core bedside question is whether the patient needs immediate platelet inhibition before coronary anatomy is known, or whether pretreatment creates avoidable harm if CABG, high bleeding risk, or a duplicate load becomes the next problem.

A common transfer scenario makes this operational: the cath lab asks whether ticagrelor was already given, the medication record is unclear, and the note only says DAPT started. The pharmacist’s job is to turn that ambiguity into a documented decision: agent, dose, time, rationale, contraindications, and the next-step plan if PCI or CABG occurs.

Key Points

  • Separate three decisions: which P2Y12 inhibitor, when to load, and whether a prior load has already occurred.
  • In NSTE-ACS, pretreatment before coronary anatomy is known can increase bleeding and complicate CABG planning.
  • Cangrelor is a procedural option when immediate IV platelet inhibition is needed during PCI.
  • The highest-yield safety pearl is a clear handoff that prevents undocumented or duplicate loading.

Pharmacology Snapshot

AgentTypical ACS LoadPractical Pearl
Clopidogrel300-600 mg POAlternative when ticagrelor or prasugrel are not suitable. Slower and more variable platelet inhibition; affected by CYP2C19 loss-of-function alleles.
Ticagrelor180 mg POPotent reversible inhibitor often favored over clopidogrel in ACS, but dyspnea, bradyarrhythmia risk, bleeding, adherence, access, and aspirin dose matter.
Prasugrel60 mg POPotent irreversible inhibitor for PCI-selected patients. Avoid with prior stroke/TIA; use caution with age 75 years or older or weight less than 60 kg. ACCOAST cautions against reflex pretreatment before anatomy is known.
Cangrelor30 mcg/kg IV bolus, then 4 mcg/kg/minRapid, reversible IV option during PCI when oral absorption, timing, or transition is problematic. It is a procedural tool, not a substitute for thoughtful oral loading.

Clinical Pearl

The question is not simply ticagrelor versus prasugrel. In NSTE-ACS, the safer first question is whether the team knows the coronary plan and whether the patient has already been loaded.

Key Evidence

SourceComparisonPractical Takeaway
PLATO1Ticagrelor vs clopidogrel in ACS.Ticagrelor reduced cardiovascular death, MI, or stroke at 12 months: 9.8% vs 11.7%; non-CABG major bleeding was higher.
TRITON-TIMI 382Prasugrel vs clopidogrel in ACS patients scheduled for PCI.Prasugrel reduced CV death, nonfatal MI, or nonfatal stroke: 9.9% vs 12.1%, with more major bleeding.
ACCOAST3Prasugrel pretreatment vs prasugrel after angiography if PCI.No ischemic benefit before anatomy was known; TIMI major bleeding increased.
ISAR-REACT 54Ticagrelor strategy vs prasugrel strategy in ACS planned invasive evaluation.Prasugrel strategy had fewer death, MI, or stroke events at 1 year, with similar major bleeding.
CHAMPION PHOENIX5Cangrelor vs clopidogrel in PCI.Cangrelor reduced early ischemic events and stent thrombosis without significantly increasing severe bleeding.

Pharmacist Decision Checklist

Confirm the phenotype

Is this STEMI primary PCI, NSTE-ACS planned invasive evaluation, or a medically managed pathway?

Find the first load

Verify EMS, ED, transfer notes, outside MAR, cath lab handoff, and medication dispense history.

Assess CABG plausibility

Consider diabetes, prior CAD, left main concern, surgical history, anatomy suspicion, and high bleeding risk.

Match agent to patient

Flag prior stroke/TIA for prasugrel, dyspnea or bradyarrhythmia concerns for ticagrelor, age, weight, cost, access, and adherence.

Cath-lab handoff minimum data set

Loaded or not loaded, agent, dose, time, contraindications, current plan for PCI or CABG, and whether cangrelor is being used.

Practice Pearl

Pretreatment should be intentional. In NSTE-ACS, do not reflexively load before the invasive plan and CABG likelihood are clear.

Prasugrel should not be reflexive before anatomy. ACCOAST showed increased bleeding without ischemic benefit when prasugrel was given before angiography in NSTE-ACS.

Prevent duplicate loading. Vague handoff language such as DAPT started is not enough. The next team needs the agent, dose, and time.

Cangrelor is a selected PCI tool. Use it when immediate IV platelet inhibition is needed and oral therapy is delayed, unreliable, or being transitioned.

Full Reference List

  1. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.
  2. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015.
  3. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369(11):999-1010.
  4. Schupke S, Neumann FJ, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381(16):1524-1534.
  5. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303-1313.
  6. Rao SV, O’Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes. J Am Coll Cardiol. 2025.
  7. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826.
  8. Clopidogrel, ticagrelor, prasugrel, and cangrelor prescribing information. DailyMed. Accessed April 28, 2026.
Tags: NSTE-ACS P2Y12 Antiplatelets Cardiology Pharmacy Friday Pearls